DE19859668A1 - Treating or preventing viral, bacterial, fungal or parasitic infections using bis-phosphonic acid compounds, also having herbicidal activity - Google Patents
Treating or preventing viral, bacterial, fungal or parasitic infections using bis-phosphonic acid compounds, also having herbicidal activityInfo
- Publication number
- DE19859668A1 DE19859668A1 DE19859668A DE19859668A DE19859668A1 DE 19859668 A1 DE19859668 A1 DE 19859668A1 DE 19859668 A DE19859668 A DE 19859668A DE 19859668 A DE19859668 A DE 19859668A DE 19859668 A1 DE19859668 A1 DE 19859668A1
- Authority
- DE
- Germany
- Prior art keywords
- viruses
- genus
- bacteria
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000002363 herbicidal effect Effects 0.000 title claims abstract description 8
- 230000003612 virological effect Effects 0.000 title description 3
- 208000036142 Viral infection Diseases 0.000 title description 2
- 230000001580 bacterial effect Effects 0.000 title description 2
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 206010017533 Fungal infection Diseases 0.000 title 1
- 208000031888 Mycoses Diseases 0.000 title 1
- 208000030852 Parasitic disease Diseases 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 230000002538 fungal effect Effects 0.000 title 1
- 241000700605 Viruses Species 0.000 claims abstract description 59
- 241000894006 Bacteria Species 0.000 claims abstract description 54
- 241001465754 Metazoa Species 0.000 claims abstract description 29
- 125000003118 aryl group Chemical group 0.000 claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 12
- 208000015181 infectious disease Diseases 0.000 claims abstract description 12
- 244000045947 parasite Species 0.000 claims abstract description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 11
- 241000233866 Fungi Species 0.000 claims abstract description 10
- 125000002252 acyl group Chemical group 0.000 claims abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 9
- 230000000855 fungicidal effect Effects 0.000 claims abstract description 8
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 6
- 239000003899 bactericide agent Substances 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- 239000000417 fungicide Substances 0.000 claims abstract description 6
- 239000004009 herbicide Substances 0.000 claims abstract description 6
- 238000011321 prophylaxis Methods 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 125000004450 alkenylene group Chemical group 0.000 claims abstract description 5
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 5
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims abstract description 4
- 150000003863 ammonium salts Chemical class 0.000 claims abstract description 4
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 3
- 150000001408 amides Chemical class 0.000 claims abstract description 3
- 239000007857 degradation product Substances 0.000 claims abstract description 3
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 3
- 230000002458 infectious effect Effects 0.000 claims abstract 3
- 239000002253 acid Substances 0.000 claims description 32
- 241000282412 Homo Species 0.000 claims description 21
- 150000007513 acids Chemical class 0.000 claims description 11
- 241000196324 Embryophyta Species 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 208000000260 Warts Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 201000010153 skin papilloma Diseases 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 229940122361 Bisphosphonate Drugs 0.000 claims description 4
- 241000186216 Corynebacterium Species 0.000 claims description 4
- 241000709687 Coxsackievirus Species 0.000 claims description 4
- 241000709661 Enterovirus Species 0.000 claims description 4
- 241000589989 Helicobacter Species 0.000 claims description 4
- 241000700721 Hepatitis B virus Species 0.000 claims description 4
- 241000724675 Hepatitis E virus Species 0.000 claims description 4
- 208000007514 Herpes zoster Diseases 0.000 claims description 4
- 241000588653 Neisseria Species 0.000 claims description 4
- 150000003868 ammonium compounds Chemical class 0.000 claims description 4
- 150000004663 bisphosphonates Chemical class 0.000 claims description 4
- 201000004792 malaria Diseases 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 208000000230 African Trypanosomiasis Diseases 0.000 claims description 3
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 3
- 206010001986 Amoebic dysentery Diseases 0.000 claims description 3
- 208000024699 Chagas disease Diseases 0.000 claims description 3
- 208000003495 Coccidiosis Diseases 0.000 claims description 3
- 241000711573 Coronaviridae Species 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical compound OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 208000037262 Hepatitis delta Diseases 0.000 claims description 3
- 241000724709 Hepatitis delta virus Species 0.000 claims description 3
- 241000709721 Hepatovirus A Species 0.000 claims description 3
- 206010023076 Isosporiasis Diseases 0.000 claims description 3
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 3
- 208000016604 Lyme disease Diseases 0.000 claims description 3
- 241000588621 Moraxella Species 0.000 claims description 3
- 241000186359 Mycobacterium Species 0.000 claims description 3
- 241000709664 Picornaviridae Species 0.000 claims description 3
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims description 3
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims description 3
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 3
- 208000005448 Trichomonas Infections Diseases 0.000 claims description 3
- 206010044620 Trichomoniasis Diseases 0.000 claims description 3
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 3
- 241000607626 Vibrio cholerae Species 0.000 claims description 3
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 208000029080 human African trypanosomiasis Diseases 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 201000000317 pneumocystosis Diseases 0.000 claims description 3
- 201000002612 sleeping sickness Diseases 0.000 claims description 3
- KBPGKWPDIYMIFV-UHFFFAOYSA-N (2-amino-2-imino-1-phosphonoethyl)phosphonic acid Chemical compound NC(=N)C(P(O)(O)=O)P(O)(O)=O KBPGKWPDIYMIFV-UHFFFAOYSA-N 0.000 claims description 2
- NHAOLKGXQFICNN-UHFFFAOYSA-N (amino-hydroxy-phosphonomethyl)phosphonic acid Chemical compound OP(=O)(O)C(O)(N)P(O)(O)=O NHAOLKGXQFICNN-UHFFFAOYSA-N 0.000 claims description 2
- 241000606750 Actinobacillus Species 0.000 claims description 2
- 241000186046 Actinomyces Species 0.000 claims description 2
- 241000203716 Actinomycetaceae Species 0.000 claims description 2
- 241000701242 Adenoviridae Species 0.000 claims description 2
- 241000607534 Aeromonas Species 0.000 claims description 2
- 241000607525 Aeromonas salmonicida Species 0.000 claims description 2
- 241000702419 Ambidensovirus Species 0.000 claims description 2
- 241000710189 Aphthovirus Species 0.000 claims description 2
- 241000712892 Arenaviridae Species 0.000 claims description 2
- 241000712891 Arenavirus Species 0.000 claims description 2
- 241000701802 Aviadenovirus Species 0.000 claims description 2
- 241000606662 Bartonellaceae Species 0.000 claims description 2
- 241000588807 Bordetella Species 0.000 claims description 2
- 241000589968 Borrelia Species 0.000 claims description 2
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 2
- 241000589562 Brucella Species 0.000 claims description 2
- 241000589877 Campylobacter coli Species 0.000 claims description 2
- 241000589875 Campylobacter jejuni Species 0.000 claims description 2
- 241001647378 Chlamydia psittaci Species 0.000 claims description 2
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 2
- 241000606069 Chlamydiaceae Species 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- 241000186225 Corynebacterium pseudotuberculosis Species 0.000 claims description 2
- 241000186427 Cutibacterium acnes Species 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 241000187831 Dermatophilus Species 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 241001466953 Echovirus Species 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims description 2
- 241000711950 Filoviridae Species 0.000 claims description 2
- 241000710781 Flaviviridae Species 0.000 claims description 2
- 241000710831 Flavivirus Species 0.000 claims description 2
- 241000711557 Hepacivirus Species 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 206010019771 Hepatitis F Diseases 0.000 claims description 2
- 241000700586 Herpesviridae Species 0.000 claims description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 2
- 241000701041 Human betaherpesvirus 7 Species 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 2
- 241000701027 Human herpesvirus 6 Species 0.000 claims description 2
- 241000829111 Human polyomavirus 1 Species 0.000 claims description 2
- 241000701460 JC polyomavirus Species 0.000 claims description 2
- 241000589248 Legionella Species 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 241000589902 Leptospira Species 0.000 claims description 2
- 241000186779 Listeria monocytogenes Species 0.000 claims description 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 2
- 241000711828 Lyssavirus Species 0.000 claims description 2
- 241001115401 Marburgvirus Species 0.000 claims description 2
- 241000701244 Mastadenovirus Species 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241000700560 Molluscum contagiosum virus Species 0.000 claims description 2
- 241000588622 Moraxella bovis Species 0.000 claims description 2
- 241000712045 Morbillivirus Species 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 241000186360 Mycobacteriaceae Species 0.000 claims description 2
- 241000186366 Mycobacterium bovis Species 0.000 claims description 2
- 241000186362 Mycobacterium leprae Species 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 2
- 241000204034 Mycoplasmataceae Species 0.000 claims description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 2
- 241000187654 Nocardia Species 0.000 claims description 2
- 241000702259 Orbivirus Species 0.000 claims description 2
- 241000150452 Orthohantavirus Species 0.000 claims description 2
- 241000712464 Orthomyxoviridae Species 0.000 claims description 2
- 241000150218 Orthonairovirus Species 0.000 claims description 2
- 241000702244 Orthoreovirus Species 0.000 claims description 2
- 241000711504 Paramyxoviridae Species 0.000 claims description 2
- 241000150350 Peribunyaviridae Species 0.000 claims description 2
- 241000713137 Phlebovirus Species 0.000 claims description 2
- 241000607568 Photobacterium Species 0.000 claims description 2
- 241000607000 Plesiomonas Species 0.000 claims description 2
- 241000711902 Pneumovirus Species 0.000 claims description 2
- 241001505332 Polyomavirus sp. Species 0.000 claims description 2
- 241000700625 Poxviridae Species 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 241000186429 Propionibacterium Species 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 241000702247 Reoviridae Species 0.000 claims description 2
- 241000711931 Rhabdoviridae Species 0.000 claims description 2
- 241000316848 Rhodococcus <scale insect> Species 0.000 claims description 2
- 241000606683 Rickettsiaceae Species 0.000 claims description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 2
- 241000702670 Rotavirus Species 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 241000589971 Spirochaetaceae Species 0.000 claims description 2
- 241000713675 Spumavirus Species 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 241000589886 Treponema Species 0.000 claims description 2
- 241000202898 Ureaplasma Species 0.000 claims description 2
- 241000713152 Uukuniemi virus Species 0.000 claims description 2
- 241000700647 Variola virus Species 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- 241000544286 Vibrio anguillarum Species 0.000 claims description 2
- 241000607493 Vibrionaceae Species 0.000 claims description 2
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 2
- 241000607447 Yersinia enterocolitica Species 0.000 claims description 2
- 241000607477 Yersinia pseudotuberculosis Species 0.000 claims description 2
- 241001148129 Yersinia ruckeri Species 0.000 claims description 2
- 108700010877 adenoviridae proteins Proteins 0.000 claims description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 2
- 230000001553 hepatotropic effect Effects 0.000 claims description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 229940098232 yersinia enterocolitica Drugs 0.000 claims description 2
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000589874 Campylobacter fetus Species 0.000 claims 1
- 208000008953 Cryptosporidiosis Diseases 0.000 claims 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 claims 1
- 241000531123 GB virus C Species 0.000 claims 1
- 241000186781 Listeria Species 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 241000186367 Mycobacterium avium Species 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- 241000713112 Orthobunyavirus Species 0.000 claims 1
- 241000710778 Pestivirus Species 0.000 claims 1
- 241000710801 Rubivirus Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- -1 ester salts Chemical class 0.000 abstract description 86
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 8
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 229910052723 transition metal Inorganic materials 0.000 abstract 1
- 150000003624 transition metals Chemical class 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 12
- 230000008029 eradication Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000004392 genitalia Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 241000589876 Campylobacter Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241001631646 Papillomaviridae Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 229940092782 bentonite Drugs 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 208000003265 stomatitis Diseases 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 206010037151 Psittacosis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 206010059394 acanthoma Diseases 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 208000007456 balantidiasis Diseases 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000011475 meningoencephalitis Diseases 0.000 description 2
- 208000026721 nail disease Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 201000000901 ornithosis Diseases 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 125000006411 1-propenylene group Chemical group [H]\C(*)=C(\[H])C([H])([H])[H] 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 240000000991 Eucalyptus amygdalina Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000589246 Legionellaceae Species 0.000 description 1
- 241000700563 Leporipoxvirus Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000589901 Leptospiraceae Species 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010031068 Orchitis mumps Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010056332 Panencephalitis Diseases 0.000 description 1
- 208000026681 Paratuberculosis Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035673 Pneumonia chlamydial Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241001430313 Propionibacteriaceae Species 0.000 description 1
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- 206010041047 Slow virus infection Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 208000000292 ehrlichiosis Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 201000004306 epidermodysplasia verruciformis Diseases 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229950006971 incadronic acid Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 208000010453 mesenteric lymphadenitis Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- AGRXSXQEULWPJL-UHFFFAOYSA-N propa-1,2-diene-1,3-diol Chemical group OC=C=CO AGRXSXQEULWPJL-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 229960000918 protionamide Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960005324 tiludronic acid Drugs 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 208000012498 virus associated tumor Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Die Erfindung betrifft die Verwendung von Bisphosphonaten als Arzneimittel zur therapeutischen und prophylaktischen Behand lung von Infektionen bei Mensch und Tier, die durch Viren, Bakterien, Pilze und Parasiten hervorgerufen werden, und ihre Verwendung als Fungizid, Bakterizid und Herbizid bei Pflanzen.The invention relates to the use of bisphosphonates as Medicinal products for therapeutic and prophylactic treatment infection of humans and animals caused by viruses, Bacteria, fungi and parasites are caused, and their Use as a fungicide, bactericide and herbicide in plants.
Die Verwendung von Bisphosphonsäuren und einigen ihrer Deriva te in Arzneimitteln ist bereits bekannt. Bislang ist die mi krobiostatische Wirksamkeit der Bisphosphonsäuren (DE 36 11 522), ihre Wirksamkeit bei der Behandlung von Störungen des Calcium- und Phosphatstoffwechsels (DE 25 34 390, DE 25 34 391, DE 33 34 211, DE 34 34 667, DE 27 45 083), die cytostati sche Wirksamkeit (DE 34 25 812), ihre lipidsenkende Wirksam keit (Arzneimittelforschung 46, 759-62) und ihre Fähigkeit, Immunzellen zu stimulieren (WO 97/38 696), bekannt.The use of bisphosphonic acids and some of their deriva te in drugs is already known. So far the mi crobiostatic activity of bisphosphonic acids (DE 36 11 522), their effectiveness in treating disorders of the Calcium and phosphate metabolism (DE 25 34 390, DE 25 34 391, DE 33 34 211, DE 34 34 667, DE 27 45 083), the cytostati cal effectiveness (DE 34 25 812), their lipid-lowering activity ability (drug research 46, 759-62) and their ability to Stimulate immune cells (WO 97/38 696), known.
Es besteht ein starker Bedarf, für die Bereicherung der Be handlung von Mensch und Tier sowie den Schutz von Pflanzen Mittel bereitzustellen, die eine starke Wirksamkeit besitzen.There is a strong need to enrich the Be action of humans and animals as well as the protection of plants To provide agents that are highly effective.
Aufgabe der vorliegenden Erfindung ist es daher, eine Substanz bereitzustellen, die universell bei Infektionen durch Viren, Bakterien, Pilze und Parasiten bei Menschen und Tieren und als Fungizid, Bakterizid und Herbizid bei Pflanzen einsetzbar ist und die oben angegebenen Bedingungen erfüllt. The object of the present invention is therefore a substance to provide universal for virus infections, Bacteria, fungi and parasites in humans and animals and as Fungicide, bactericide and herbicide can be used in plants and meets the above conditions.
Diese Aufgabe wird in völlig überraschender Weise durch die in Anspruch 1 definierte Stoffgruppe gelöst. Diese Stoffgruppe zeigt eine antiinfektiöse Wirkung gegen Viren, Bakterien, Pil ze, ein- und mehrzellige Parasiten als auch eine fungizide, bakterizide und herbizide Wirkung bei Pflanzen.This task is accomplished in a completely surprising way by the in Claim 1 defined substance group solved. This group of substances shows an anti-infectious effect against viruses, bacteria, pil ze, single and multicellular parasites as well as a fungicidal, bactericidal and herbicidal activity in plants.
Die vorliegende Erfindung betrifft daher die Verwendung von
Bisphosphonsäuren. Als Bisphosphonsäuren und deren Derivate
werden solche der allgemeinen Formel
The present invention therefore relates to the use of bisphosphonic acids. Bisphosphonic acids and their derivatives are those of the general formula
eingesetzt, worin
A1, A2, A3, A4, die gleich oder verschieden sein können, aus
der Gruppe ausgewählt sind, die aus Wasserstoff, substituier
tem und unsubstituiertem Alkyl, substituiertem und unsubstitu
iertem Aryl, substituiertem und unsubstituiertem Aralkyl, sub
stituiertem und unsubstituiertem Cycloalkyl, substituiertem
und unsubstituiertem heterocyclischen Rest, Metallen der 1.,
2. und 3. Hauptgruppe des periodischen Systems, wie Na, K, Ca,
Mg, Al sowie substituiertem und unsubstituiertem Ammonium und
Ammoniumverbindungen, die sich von Ethylendiamin oder Ami
nosäuren ableiten, besteht,
X, das auch wegfallen kann, aus der Gruppe ausgewählt ist, die
aus Alkylen, Alkenylen und Hydroxyalkylen besteht,
R1, R2, die gleich oder verschieden sein können, aus der Grup
pe ausgewählt sind, die aus H, OH, -NH2, substituiertem und
unsubstituiertem Acyl, substituiertem und unsubstituiertem Al
kyl, substituiertem und unsubstituiertem Aryl, substituiertem
und unsubstituiertem Cycloalkyl, substituiertem und unsubsti
tuiertem Aralkyl, substituiertem und unsubstituiertem he
terocyclischen Rest und -SR3, Cl und -NR3R4 besteht, worin
R3, R4, die gleich oder verschieden sein können, aus der Gruppe
ausgewählt sind, die aus H, OH, substituiertem und unsubstitu
iertem Acyl, substituiertem und unsubstituiertem Alkyl, sub
stituiertem und unsubstituiertem Aryl, substituiertem und un
substituiertem Aralkyl, substituiertem und unsubstituiertem
Cycloalkyl und substituiertem und unsubstituiertem heterocy
clischen Rest besteht, und
deren pharmazeutisch verträglichen Salze, Amide, Ester sowie
Salze der Ester oder Verbindungen, die bei Applikation die zu
verabreichenden Verbindungen als Stoffwechsel- oder Abbaupro
dukte bilden.used where
A 1 , A 2 , A 3 , A 4 , which may be the same or different, are selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted Cycloalkyl, substituted and unsubstituted heterocyclic radical, metals of the 1st, 2nd and 3rd main group of the periodic system, such as Na, K, Ca, Mg, Al and substituted and unsubstituted ammonium and ammonium compounds derived from ethylenediamine or amino acids, consists,
X, which can also be omitted, is selected from the group consisting of alkylene, alkenylene and hydroxyalkylene,
R 1 , R 2 , which may be the same or different, are selected from the group consisting of H, OH, -NH 2 , substituted and unsubstituted acyl, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted cycloalkyl , substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic radical and -SR 3 , Cl and -NR 3 R 4 , wherein R 3 , R 4 , which may be the same or different, are selected from the group consisting of H , OH, substituted and unsubstituted acyl, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted cycloalkyl and substituted and unsubstituted heterocyclic radical, and
their pharmaceutically acceptable salts, amides, esters and salts of the esters or compounds which, when administered, form the compounds to be administered as metabolic or degradation products.
Besonderheiten der obigen Definitionen und geeignete Beispiele
dafür werden nachfolgend angegeben:
"Acyl" ist ein Substituent, der von einer Säure stammt, wie
von einer organischen Carbonsäure, Kohlensäure, Carbaminsäure
oder der den einzelnen vorstehenden Säuren entsprechenden
Thiosäure oder Imidsäure, oder von einer organischen Sulfon
säure, wobei diese Säuren jeweils aliphatische, aromatische
und/oder heterocyclische Gruppen im Molekül umfassen sowie
Carbamoyl oder Carbamimidoyl.Special features of the above definitions and suitable examples are given below:
"Acyl" is a substituent derived from an acid, such as from an organic carboxylic acid, carbonic acid, carbamic acid or the thioic acid or imidic acid corresponding to the individual acids above, or from an organic sulfonic acid, these acids each being aliphatic, aromatic and / or include heterocyclic groups in the molecule as well as carbamoyl or carbamimidoyl.
Geeignete Beispiele für diese Acylgruppen werden nachfolgend angegeben.Suitable examples of these acyl groups are shown below specified.
Als aliphatische Acylgruppen werden von einer aliphatischen
Säure stammende Acylreste bezeichnet, zu denen die folgenden
gehören:
Alkanoyl (z. B. Formyl, Acetyl, Propionyl, Butyryl, Isobutyryl,
Valeryl, Isovaleryl, Pivaloyl etc.);
Alkenoyl (z. B. Acryloyl, Methacryloyl, Crotonoyl etc.);
Alkylthioalkanoyl (z. B. Methylthioacetyl, Ethylthioacetyl
etc.)
Alkansulfonyl (z. B. Mesyl, Ethansulfonyl, Propansulfonyl
etc.);
Alkoxycarbonyl (z. B. Methoxycarbonyl, Ethoxycarbonyl, Propoxy
carbonyl, Isopropoxycarbonyl, Butoxycarbonyl, Isobutoxycar
bonyl etc.);
Alkylcarbamoyl (z. B. Methylcarbamoyl etc.);
(N-Alkyl)-thiocarbamoyl (z. B. (N-Methyl)-thiocarbamoyl etc.);
Alkylcarbamimidoyl (z. B. Methylcarbamimidoyl etc.);
Oxalo;
Alkoxalyl (z. B. Methoxalyl, Ethoxalyl, Propoxalyl etc.).Aliphatic acyl groups are acyl radicals derived from an aliphatic acid, which include the following:
Alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl etc.);
Alkenoyl (e.g. acryloyl, methacryloyl, crotonoyl etc.);
Alkylthioalkanoyl (e.g. methylthioacetyl, ethylthioacetyl etc.)
Alkanesulfonyl (e.g. mesyl, ethanesulfonyl, propanesulfonyl, etc.);
Alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxy carbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, etc.);
Alkyl carbamoyl (e.g. methyl carbamoyl etc.);
(N-alkyl) thiocarbamoyl (e.g. (N-methyl) thiocarbamoyl etc.);
Alkyl carbamimidoyl (e.g. methyl carbamimidoyl etc.);
Oxalo;
Alkoxalyl (e.g. methoxalyl, ethoxalyl, propoxalyl etc.).
Bei den obigen Beispielen für aliphatische Acylgruppen kann der aliphatische Kohlenwasserstoffteil, insbesondere die Al kylgruppe bzw. der Alkanrest, ggf. einen oder mehrere geeigne te Substituenten aufweisen, wie Amino, Halogen (z. B. Fluor, Chlor, Brom etc.), Hydroxy, Hydroxyimino, Carboxy, Alkoxy (z. B. Methoxy, Ethoxy, Propoxy etc.), Alkoxycarbonyl, Acylami no (z. B. Benzyloxycarbonylamino etc.), Acyloxy (z. B. Acetoxy, Benzoyloxy etc.) und dergleichen; als bevorzugte aliphatische Acylreste mit solchen Substituenten sind z. B. mit Amino, Car boxy, Amino und Carboxy, Halogen, Acylamino oder dergleichen substituierte Alkanoyle zu nennen.In the above examples of aliphatic acyl groups the aliphatic hydrocarbon part, especially the Al kylgruppe or the alkane radical, optionally one or more suitable have substituents such as amino, halogen (e.g. fluorine, Chlorine, bromine etc.), hydroxy, hydroxyimino, carboxy, alkoxy (e.g. methoxy, ethoxy, propoxy etc.), alkoxycarbonyl, acylami no (e.g. benzyloxycarbonylamino etc.), acyloxy (e.g. acetoxy, Benzoyloxy etc.) and the like; as the preferred aliphatic Acyl radicals with such substituents are e.g. B. with amino, car boxy, amino and carboxy, halogen, acylamino or the like to name substituted alkanoyle.
Als aromatische Acylreste werden solche Acylreste bezeichnet,
die von einer Säure mit substituierter oder nicht substituier
ter Arylgruppe stammen, wobei die Arylgruppe Phenyl, Tolyl,
Xylyl, Naphthyl und dergleichen umfassen kann; geeignete Bei
spiele werden nachfolgend angegeben:
Aroyl (z. B. Benzoyl, Toluoyl, Xyloyl, Naphthoyl, Phthaloyl
etc.);
Aralkanoyl (z. B. Phenylacetyl etc.);
Aralkenoyl (z. B. Cinnamoyl etc.);
Aryloxyalkanoyl (z. B. Phenoxyacetyl etc.);
Arylthioalkanoyl (z. B. Phenylthioacetyl etc.);
Arylaminoalkanoyl (z. B. N-Phenylglycyl, etc.);
Arensulfonyl (z. B. Benzolsulfonyl, Tosyl bzw. Toluolsulfonyl,
Naphthalinsulfonyl etc.);
Aryloxycarbonyl (z. B. Phenoxycarbonyl, Naphthyl-oxycarbonyl
etc.);
Aralkoxycarbonyl (z. B. Benzyloxycarbonyl etc.);
Arylcarbamoyl (z. B. Phenylcarbamoyl, Naphthylcarbamoyl etc.);
Arylglyoxyloyl (z. B. Phenylglyoxyloyl etc.).
Aromatic acyl radicals are those acyl radicals which derive from an acid having a substituted or unsubstituted aryl group, where the aryl group can include phenyl, tolyl, xylyl, naphthyl and the like; Suitable examples are given below:
Aroyl (e.g. benzoyl, toluoyl, xyloyl, naphthoyl, phthaloyl etc.);
Aralkanoyl (e.g. phenylacetyl etc.);
Aralkenoyl (e.g. cinnamoyl etc.);
Aryloxyalkanoyl (e.g. phenoxyacetyl etc.);
Arylthioalkanoyl (e.g. phenylthioacetyl etc.);
Arylaminoalkanoyl (e.g. N-phenylglycyl, etc.);
Arenesulfonyl (e.g. benzenesulfonyl, tosyl or toluenesulfonyl, naphthalenesulfonyl, etc.);
Aryloxycarbonyl (e.g. phenoxycarbonyl, naphthyloxycarbonyl etc.);
Aralkoxycarbonyl (e.g. benzyloxycarbonyl etc.);
Arylcarbamoyl (e.g. phenylcarbamoyl, naphthylcarbamoyl etc.);
Arylglyoxyloyl (e.g. phenylglyoxyloyl etc.).
Bei den vorstehenden Beispielen für aromatische Acylreste kann
der aromatische Kohlenwasserstoffteil (insbesondere der Aryl
rest) und/oder der aliphatische Kohlenwasserstoffteil (insbe
sondere der Alkanrest) ggf. ein oder mehrere geeignete Substi
tuenten aufweisen, wie solche, die als geeignete Substituenten
für die Alkylgruppe bzw. den Alkanrest bereits angegeben wur
den. Insbesondere und als Beispiel für bevorzugte aromatische
Acylreste mit besonderen Substituenten werden mit Halogen und
Hydroxy oder mit Halogen und Acyloxy substituiertes Aroyl und
mit Hydroxy, Hydroxyimino, Dihalogenalkanoyloxyimino substitu
iertes Aralkanoyl angegeben sowie
Arylthiocarbamoyl (z. B. Phenylthiocarbamoyl etc.);
Arylcarbamimidoyl (z. B. Phenylcarbamimidoyl etc.).In the above examples of aromatic acyl radicals, the aromatic hydrocarbon part (in particular the aryl radical) and / or the aliphatic hydrocarbon part (in particular the alkane radical) can optionally have one or more suitable substituents, such as those which are suitable substituents for the alkyl group or the alkane residue has already been given. In particular and as an example of preferred aromatic acyl radicals with special substituents, arylanoyl substituted with halogen and hydroxy or with halogen and acyloxy and aralkanoyl substituted with hydroxy, hydroxyimino, dihalogenalkanoyloxyimino are also given
Arylthiocarbamoyl (e.g. phenylthiocarbamoyl etc.);
Arylcarbamimidoyl (e.g. phenylcarbamimidoyl etc.).
Als heterocyclischer Acylrest wird ein Acylrest verstanden,
der von einer Säure mit heterocyclischer Gruppe stammt; dazu
gehören:
Heterocyclisches Carbonyl, bei dem der heterocyclische Rest
ein aromatischer oder aliphatischer 5-bis 6-gliedriger He
terocyclus mit zumindest einem Heteroatom aus der Gruppe
Stickstoff, Sauerstoff und Schwefel ist (z. B. Thiophenyl, Fu
royl, Pyrrolcarbonyl, Nicotinoyl etc.);
Heterocyclus-Alkanoyl, bei dem der heterocyclische Rest 5- bis
6-gliedrig ist und zumindest ein Heteroatom aus der Gruppe
Stickstoff, Sauerstoff und Schwefel aufweist (z. B. Thiophen
yl-acetyl, Furylacetyl, Imidazolylpropionyl, Tetrazolylacetyl,
2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetyl etc.) und der
gleichen.
A heterocyclic acyl radical is understood to mean an acyl radical which comes from an acid with a heterocyclic group; this includes:
Heterocyclic carbonyl, in which the heterocyclic radical is an aromatic or aliphatic 5 to 6-membered heterocycle with at least one heteroatom from the group consisting of nitrogen, oxygen and sulfur (e.g. thiophenyl, fu royl, pyrrole carbonyl, nicotinoyl etc.);
Heterocycle alkanoyl, in which the heterocyclic radical is 5- to 6-membered and has at least one heteroatom from the group consisting of nitrogen, oxygen and sulfur (e.g. thiophene yl-acetyl, furylacetyl, imidazolylpropionyl, tetrazolylacetyl, 2- (2- Amino-4-thiazolyl) -2-methoxyiminoacetyl etc.) and the like.
Bei den obigen Beispielen für heterocyclische Acylreste kann der Heterocyclus und/oder der aliphatische Kohlenwasserstoff teil ggf. einen oder mehrere geeignete Substituenten aufwei sen, wie die gleichen, die als geeignet für Alkyl- und Alkan gruppen angegeben wurden.In the above examples of heterocyclic acyl residues the heterocycle and / or the aliphatic hydrocarbon some may have one or more suitable substituents sen, like the same ones that are suitable for alkyl and alkane groups were specified.
"Alkyl" ist ein gerad- oder verzweigtkettiger Alkylrest mit bis zu 9 Kohlenstoffatomen, wie Methyl, Ethyl, Propyl, Isopro pyl, Butyl, Isobutyl, tert.-Butyl, Pentyl, Hexyl und derglei chen."Alkyl" is a straight or branched chain alkyl group with up to 9 carbon atoms, such as methyl, ethyl, propyl, isopro pyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like chen.
Cycloalkyl steht vorzugsweise für ein ggfs. substituiertes C3- C7-Cycloalkyl; als mögliche Substituenten sind u. a. Alkyl, Al koxy (z. B. Methoxy, Ethoxy etc.), Halogen (z. B. Fluor, Chlor, Brom etc.), Nitro und dergleichen geeignet.Cycloalkyl preferably represents an optionally substituted C 3 -C 7 cycloalkyl; possible substituents include alkyl, alkoxy (e.g. methoxy, ethoxy etc.), halogen (e.g. fluorine, chlorine, bromine etc.), nitro and the like.
Aryl ist ein aromatischer Kohlenwasserstoffrest, wie Phenyl Naphthyl usw., der ggf. einen oder mehrere geeignete Substitu enten aufweisen kann wie Alkoxy (z. B. Methoxy, Ethoxy etc.), Halogen (z. B. Fluor, Chlor, Brom etc.), Nitro und dergleichen.Aryl is an aromatic hydrocarbon residue, such as phenyl Naphthyl, etc., which optionally one or more suitable substituents can have ducks such as alkoxy (e.g. methoxy, ethoxy etc.), Halogen (e.g. fluorine, chlorine, bromine, etc.), nitro and the like.
Zu "Aralkyl" gehören Mono-, Di-, Triphenylalkyle wie Benzyl, Phenethyl, Benzhydryl, Trityl und dergleichen, wobei der aro matische Teil ggf. ein oder mehrere geeignete Substituenten aufweisen kann wie Alkoxy (z. B. Methoxy, Ethoxy etc.), Halogen (z. B. Fluor, Chlor, Brom etc.), Nitro und dergleichen."Aralkyl" includes mono-, di-, triphenylalkyls such as benzyl, Phenethyl, benzhydryl, trityl and the like, the aro Matic part optionally one or more suitable substituents may have such as alkoxy (e.g. methoxy, ethoxy etc.), halogen (e.g. fluorine, chlorine, bromine, etc.), nitro and the like.
Zu "Alkylen" gehören gerad- oder verzweigtkettige Alkylengrup
pen, die bis zu 9 Kohlenstoffatome aufweisen und durch die
Formel
"Alkylene" includes straight-chain or branched-chain alkylene groups which have up to 9 carbon atoms and are represented by the formula
-(CnH2n)-
- (C n H 2n ) -
wiedergegeben werden können, in der n eine ganze Zahl von 1 bis 9 ist, wie Methylen, Ethylen, Trimethylen, Methylethylen, Tetramethylen, 1-Methyltrimethylen, 2-Ethylethylen, Pentame thylen, 2-Methyltetramethylen, Isopropylethylen, Hexamethylen, und dergleichen; bevorzugte Alkylenreste haben bis zu 4 Koh lenstoffatome und besonders bevorzugt sind Reste mit 3 Kohlen stoffatomen wie z. B. Trimethylen.can be reproduced in which n is an integer of 1 to 9, such as methylene, ethylene, trimethylene, methylethylene, Tetramethylene, 1-methyltrimethylene, 2-ethylethylene, pentame ethylene, 2-methyltetramethylene, isopropylethylene, hexamethylene, and the same; preferred alkylene radicals have up to 4 Koh Linen atoms and residues with 3 carbons are particularly preferred atoms such as B. Trimethylene.
Zu "Alkenylen" gehören gerad- oder verzweigtkettige Alkenylen
gruppen mit bis zu 9 Kohlenstoffatomen, die durch die Formel
"Alkenylene" includes straight or branched chain alkenylene groups with up to 9 carbon atoms, which are represented by the formula
-(CnH2n-2)-
- (C n H 2n-2 ) -
wiedergegeben werden können, in der n eine ganze Zahl von 2 bis 9 ist, wie z. B. Vinylen, Propenylen (z. B. 1-Propenylen, 2- Propenylen), 1-Methylpropenylen, 2-Methylpropenylen, Buteny len, 2-Ethylpropenylen, Pentenylen, Hexenylen und dergleichen; besonders bevorzugt kann der Alkenylenrest bis zu 5 Kohlen stoffatome aufweisen und insbesondere 3 Kohlenstoffatome wie z. B. 1-Propenylen.can be reproduced in which n is an integer of 2 to 9, such as B. vinylene, propenylene (e.g. 1-propenylene, 2- Propenylene), 1-methylpropenylene, 2-methylpropenylene, buteny len, 2-ethylpropenylene, pentenylene, hexenylene and the like; the alkenylene radical can particularly preferably contain up to 5 carbons Have substance atoms and in particular 3 carbon atoms such as e.g. B. 1-propenylene.
Zu "Hydroxyalkylen" gehören gerad- oder verzweigtkettige Alky
lenreste, die bis zu 9 Kohlenstoffatome aufweisen, wobei ein
oder mehrere ausgewählte Kohlenstoffatome mit einer Hydroxy
gruppe substituiert ist; diese Reste können durch die Formel
"Hydroxyalkylene" includes straight or branched chain alkylene residues which have up to 9 carbon atoms, one or more selected carbon atoms being substituted by a hydroxyl group; these residues can be represented by the formula
-(CnH2n-z)(OH)z-
- (C n H 2n-z ) (OH) z -
wiedergegeben werden, in der n eine ganze Zähl von 1 bis 9 ist und z eine ganze Zahl von 1 bis 9 ist, für die z ≦ n gilt. Zu geeigneten Beispielen für solche Hydroxyalkylengruppen gehören Hydroxymethylen, Hydroxyethylen (z. B. 1-Hydroxyethylen und 2- Hydroxyethylen), Hydroxytrimethylen (z. B. 1-Hydroxytrimethy len, 2-Hydroxytrimethylen und 3-Hydroxytrimethylen), Hydroxy tetra-methylen (z. B. 2-Hydroxytetramethylen), 2-Hydroxy-2- methyltri-methylen, Hydroxypentamethylen (z. B. 2-Hydroxypenta methylen), Hydroxyhexamethylen (z. B. 2-Hydroxyhexamethylen) und dergleichen. Besonders bevorzugt wird ein niederes Hy droxyalkylen mit bis zu 4 Kohlenstoffatomen und insbesondere ein solches mit 3 Kohlenstoffatomen wie z. B. 2-Hydroxytri methylen.are reproduced in which n is an integer from 1 to 9 and z is an integer from 1 to 9 for which z ≦ n applies. To suitable examples of such hydroxyalkylene groups include Hydroxymethylene, hydroxyethylene (e.g. 1-hydroxyethylene and 2- Hydroxyethylene), hydroxytrimethylene (e.g. 1-hydroxytrimethy len, 2-hydroxytrimethylene and 3-hydroxytrimethylene), hydroxy tetra-methylene (e.g. 2-hydroxytetramethylene), 2-hydroxy-2- methyltri-methylene, hydroxypentamethylene (e.g. 2-hydroxypenta methylene), hydroxyhexamethylene (e.g. 2-hydroxyhexamethylene) and the same. A lower Hy is particularly preferred droxyalkylene with up to 4 carbon atoms and in particular one with 3 carbon atoms such. B. 2-Hydroxytri methylene.
"Heterocyclischer Rest" ist vorzugsweise ein aromatischer oder aliphatischer 5-bis 6-gliedriger Heterocyclus mit zumindest einem Heteroatom aus der Gruppe Stickstoff, Sauerstoff und Schwefel (z. B. Thiophenyl, Furoyl, Pyrrolcarbonyl, Nicotinoyl etc.)."Heterocyclic radical" is preferably an aromatic or aliphatic 5 to 6-membered heterocycle with at least a heteroatom from the group nitrogen, oxygen and Sulfur (e.g. thiophenyl, furoyl, pyrrolcarbonyl, nicotinoyl Etc.).
Als besonders wirksam haben sich die Bisphosphonsäuren Amino-hydroxy-methyliden-bisphosphonsäure (AMP), 2-Amino-1-hydroxyethyliden-1,1-bisphosphonsäure (AEP), 3-Amino-1-hydroxypropyliden-1,1-bisphosphonsäure (Pamidronsäu re), 4-Amino-1-hydroxybutyliden-1,1-bisphosphonsäure (Alendronsäu re), 6-Amino-1-hydroxyhexyliden-1,1-bisphosphonsäure (AHP), Amidinomethylen-bisphosphonsäure (AIMP), 3-Methylpentylamino-1-hydroxypropyliden-1,1-bisphosphonsäure (Ibandronsäure), 2-(3-Pyridinyl)-1-hydroxyethyliden-bisphosphonsäure (Risedron säure), 1-Hydroxy-2-(imidazol-1-yl)-ethyliden-1,1-bisphosphonsäure (Zoledronsäure), Cycloheptylaminomethylendiphosphonsäure (Cimadronsäure), 4-Chlorphenyl-thiomethylen-1,1-bisphosphonsäure (Tiludronsäu re) sowie deren Derivate erwiesen.The bisphosphonic acids have been found to be particularly effective Amino-hydroxy-methylidene-bisphosphonic acid (AMP), 2-amino-1-hydroxyethylidene-1,1-bisphosphonic acid (AEP), 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid (pamidronic acid re), 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (alendronic acid re), 6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid (AHP), Amidinomethylene bisphosphonic acid (AIMP), 3-methylpentylamino-1-hydroxypropylidene-1,1-bisphosphonic acid (Ibandronic acid), 2- (3-pyridinyl) -1-hydroxyethylidene bisphosphonic acid (Risedron acid), 1-hydroxy-2- (imidazol-1-yl) ethylidene-1,1-bisphosphonic acid (Zoledronic acid), Cycloheptylaminomethylene diphosphonic acid (cimadronic acid), 4-chlorophenyl-thiomethylene-1,1-bisphosphonic acid (tiludronic acid re) and their derivatives.
Die Verbindungen sind insbesondere für die therapeutische und prophylaktischen Behandlung von Infektionen bei Mensch und Tier geeignet, die durch Viren, Bakterien, ein- und mehrzelli ge Parasiten und Pilze hervorgerufen werden.The compounds are particularly therapeutic and prophylactic treatment of infections in humans and Suitable for animals caused by viruses, bacteria, unicellular and multicellular parasites and fungi.
Die Verbindungen sind insbesondere gegen die folgenden einzel ligen Parasiten (Protozoen) wirksam, gegen Erreger der Malaria und der Schlafkrankheit sowie der Chagas-Krankheit, der Toxoplasmose, der Amöbenruhr, der Leishmaniosen, der Trichomo niasis, der Pneumozystose, der Balantidiose, der Kryptospori diose, der Sarkozystose, der Akanthamöbose, der Naeglerose, der Kokzidiose, der Giardiose und der Lambliose.The compounds are particularly against the following individual only parasites (protozoa) are effective against malaria pathogens and sleeping sickness as well as Chagas disease, the Toxoplasmosis, the amoebic dysentery, the leishmaniasis, the trichomo niasis, pneumocystosis, balantidiosis, cryptospori diose, sarcolocystosis, acanthoma, nail disease, coccidiosis, giardiosis and lambliosis.
Sie sind daher insbesondere als Malariaprophylaxe und als Pro phylaxe der Schlafkrankheit sowie der Chagas-Krankheit, der Toxoplasmose, der Amöbenruhr, der Leishmaniosen, der Trichomo niasis, der Pneumozystose, der Balantidiose, der Kryptospori diose, der Sarkozystose, der Akanthamöbose, der Naeglerose, der Kokzidiose, der Giardiose und der Lambliose geeignet.They are therefore especially as malaria prophylaxis and as a pro prevention of sleeping sickness and Chagas disease, the Toxoplasmosis, the amoebic dysentery, the leishmaniasis, the trichomo niasis, pneumocystosis, balantidiosis, cryptospori diose, sarcolocystosis, acanthoma, nail disease, coccidiosis, giardiosis and lambliosis.
Die erfindungsgemäßen Wirkstoffe sind insbesondere gegen die
folgenden Bakterien einsetzbar:
Bakterien der Familie Propionibacteriaceae, insbesondere der
Gattung Propionibacterium, insbesondere die Art Propionibacte
rium acnes,
Bakterien der Familie Actinomycetaceae, insbesondere der Gat
tung Actinomyces,
Bakterien der Gattung Corynebacterium, insbesondere die Arten
Corynebacterium diphteriae und Corynebacterium pseudotubercu
losis,
Bakterien der Familie Mycobacteriaceae, der Gattung Mycobacte
rium, insbesondere die Arten Mycobacterium leprae, Mycobacte
rium tuberculosis, Mycobacterium bovis und Mycobacterium avi
um,
Bakterien der Familie Chlamydiaceae, insbesondere die Spezies
Chlamydia trachomatis und Chlamydia psittaci,
Bakterien der Gattung Listerle, insbesondere die Art Listeria
monocytogenes,
Bakterien der Art Erysipelthrix rhusiopathiae,
Bakterien der Gattung Clostridium,
Bakterien der Gattung Yersinia, der Spezies Yersinia pestis,
Yersinia pseudotuberculosis, Yersinia enterocolitica und Yer
sinia ruckeri,
Bakterien der Familie Mycoplasmataceae, der Gattungen My
coplasma und Ureaplasma, insbesondere die Art Mycoplasma pneu
moniae,
Bakterien der Gattung Brucella,
Bakterien der Gattung Bordetella,
Bakterien der Familie Neiseriaceae, insbesondere der Gattungen
Neisseria und Moraxella, insbesondere die Arten Neisseria me
ningitides, Neisseria gonorrhoeae und Moraxella bovis,
Bakterien der Familie Vibrionaceae, insbesondere der Gattungen
Vibrio, Aeromonas, Plesiomonas und Photobacterium, insbesonde
re die Arten Vibrio cholerae, Vibrio anguillarum und Aeromonas
salmonicidas,
Bakterien der Gattung Campylobacter, insbesondere die Arten
Campylobacter jejuni, Campylobacter coli und Campylobacter fe
tus,
Bakterien der Gattung Helicobacter, insbesondere die Art Heli
cobacter pylori,
Bakterien der Familien Spirochaetaceae und der Leptospiraceae,
insbesondere der Gattungen Treponema, Borrelia und Leptospira,
insbesondere Borrelia burgdorferi,
Bakterien der Gattung Actinobacillus,
Bakterien der Familie Legionellaceae, der Gattung Legionella,
Bakterien der Familie Rickettsiaceae und Familie Bartonella
ceae,
Bakterien der Gattungen Nocardia und Rhodococcus,
Bakterien der Gattung Dermatophilus.The active compounds according to the invention can be used in particular against the following bacteria:
Bacteria of the Propionibacteriaceae family, in particular of the Propionibacterium genus, in particular the Propionibacte rium acnes species,
Bacteria of the Actinomycetaceae family, in particular the Actinomyces gate,
Bacteria of the genus Corynebacterium, in particular the species Corynebacterium diphteriae and Corynebacterium pseudotubercu losis,
Bacteria of the family Mycobacteriaceae, of the genus Mycobacte rium, in particular the species Mycobacterium leprae, Mycobacte rium tuberculosis, Mycobacterium bovis and Mycobacterium avi um,
Bacteria of the family Chlamydiaceae, in particular the species Chlamydia trachomatis and Chlamydia psittaci,
Bacteria of the genus Listerle, in particular the species Listeria monocytogenes,
Bacteria of the species Erysipelthrix rhusiopathiae,
Bacteria of the genus Clostridium,
Bacteria of the genus Yersinia, of the species Yersinia pestis, Yersinia pseudotuberculosis, Yersinia enterocolitica and Yer sinia ruckeri,
Bacteria of the family Mycoplasmataceae, the genera My coplasma and Ureaplasma, especially the species Mycoplasma pneu moniae,
Bacteria of the genus Brucella,
Bacteria of the genus Bordetella,
Bacteria of the family Neiseriaceae, in particular of the genera Neisseria and Moraxella, in particular the species Neisseria me ningitides, Neisseria gonorrhoeae and Moraxella bovis,
Bacteria of the Vibrionaceae family, in particular of the Vibrio, Aeromonas, Plesiomonas and Photobacterium genera, in particular the Vibrio cholerae, Vibrio anguillarum and Aeromonas salmonicidas species,
Bacteria of the genus Campylobacter, in particular the species Campylobacter jejuni, Campylobacter coli and Campylobacter fe tus,
Bacteria of the genus Helicobacter, in particular the species Heli cobacter pylori,
Bacteria from the Spirochaetaceae and Leptospiraceae families, in particular the Treponema, Borrelia and Leptospira genera, in particular Borrelia burgdorferi
Bacteria of the genus Actinobacillus,
Bacteria of the Legionellaceae family, the genus Legionella,
Bacteria of the family Rickettsiaceae and family Bartonella ceae,
Bacteria of the genera Nocardia and Rhodococcus,
Bacteria of the genus Dermatophilus.
Damit eignen sich Bisphosphonsäuren und ihre Derivate zur Be handlung der Diphterie, der Acne vulgaris, der Listeriosen, des Rotlaufs bei Tieren, der Gasbrand beim Mensch und beim Tier, Pararauschbrand bei Mensch und Tier, Tuberkulose bei Mensch und Tier, Lepra, und weitere Mykobacteriosen bei Mensch und Tier, der Paratuberkulose der Tiere, Pest, mesenterialen Lymphadenitis und Pseudotuberkulose bei Mensch und Tier, Cho lera, Legionärskrankheit, Borreliose bei Mensch und Tier, Lep tospirosen bei Mensch und Tier, Syphilis, Campylobacter- Enteritiden bei Mensch und Tier, Moraxella-Keratokonjunc tivitis und Serositis der Tiere, Brucellosen der Tiere und des Menschen, Milzbrand bei Mensch und Tier, Aktinomykose bei Mensch und Tier, Streptotrichosen, Psittakose/Ornithose bei Tieren, Q-Fieber, Ehrlichiose.This makes bisphosphonic acids and their derivatives suitable for loading act of diphtheria, acne vulgaris, listeriosis, of the erysipelas in animals, the gas fire in humans and in Animal, para-raging fire in humans and animals, tuberculosis in Humans and animals, leprosy, and other mycobacteriosis in humans and animal, paratuberculosis of animals, plague, mesenteric Lymphadenitis and pseudotuberculosis in humans and animals, Cho lera, Legionnaires' disease, Lyme disease in humans and animals, Lep tospirosis in humans and animals, syphilis, Campylobacter Enteritides in humans and animals, Moraxella keratoconjunc tivitis and serositis of animals, brucellosis of animals and Humans, anthrax in humans and animals, actinomycosis in Humans and animals, streptotrichoses, psittacosis / ornithosis Animals, Q fever, Ehrlichiosis.
Weiter ist der Einsatz nützlich bei der Helicobacter- Eradikationstherapie bei Ulcera des Magendarmtraktes.The use is also useful in the Helicobacter Eradication therapy for ulcers of the gastrointestinal tract.
Es können auch Kombination mit einem weiteren Antibiotikum zur Behandlung der obengenannten Erkrankungen eingesetzt werden. Für Kombinationspräparate mit anderen Antiinfektiva eignen sich insbesondere Isoniazid, Rifampicin, Ethambutol, Pyrazina mid, Streptomycin, Protionamid und Dapson zur Behandlung der Tuberkulose.It can also be used in combination with another antibiotic Treatment of the above diseases can be used. Suitable for combination preparations with other anti-infectives in particular isoniazid, rifampicin, ethambutol, pyrazina mid, streptomycin, protionamide and dapsone for the treatment of Tuberculosis.
Die erfindungsgemäßen Wirkstoffe sind ferner insbesondere bei
Infektionen mit folgenden Viren einsetzbar:
Parvoviridae: Parvoviren, Dependoviren, Densoviren,
Adenoviridae: Adenoviren, Mastadenoviren, Aviadenoviren,
Papovaviridae: Papovaviren, insbesondere Papillomaviren (soge
nannte Warzenviren), Polyomaviren, insbesondere JC-Virus, BK-
Virus, und Miopapovaviren,
Herpesviridae: Alle Herpesviren, insbesondere Herpes-Simplex-
Viren, der Varizellen/Zoster-Viren, menschlicher Zytomegalie
virus, Epstein-Barr-Viren, alle humanen Herpesviren, humanes
Herpesvirus 6, Humanes Herpesvirus 7, humanes Herpesvirus 8,
Poxviridae: Pockenviren, Orthopox-, Parapox-, Molluscum-
Contagiosum-Virus, Aviviren, Capriviren, Leporipoxviren,
alle primär hepatotropen Viren, Hepatitisviren: Hepatitis-A-
Viren, Hepatitis-B-Viren, Hepatitis-C-Viren, Hepatitis-D-
Viren, Hepatitis-E-Viren, Hepatitis-F-Viren, Hepatits-G-Viren,
Hepadnaviren: sämtliche Hepatitisviren, Hepatitis-B-Virus, He
patitis-D-Viren,
Picornaviridae: Picornaviren, alle Enteroviren, alle Poliovi
ren, alle Coxsackieviren, alle Echoviren, alle Rhinoviren, He
patitis-A-Virus, Aphthoviren,
Calciviridae: Hepatitis-E-Viren,
Reoviridae: Reoviren, Orbiviren, Rotaviren,
Togaviridae: Togaviren, Alphaviren,, Rubiviren, Pestiviren,
Rubellavirus,
Flaviviridae: Flaviviren, FSME-Virus, Hepatitis-C-Virus,
Orthomyxoviridae: Alle Influenzaviren,
Paramyxoviridae: Paramyxoviren, Morbillivirus, Pneumovirus,
Masernvirus, Mumpsvirus,
Rhabdoviridae: Rhabdoviren, Rabiesvirus, Lyssavirus, viskulä
res Stomatitisvirus,
Coronaviridae: Coronaviren,
Bunyaviridae: Bunyaviren, Nairovirus, Phlebovirus, Uukuvirus,
Hantavirus,
Arenaviridae: Arenaviren, lymphozytäres Choriomeningitis-
Virus,
Retroviridae: Retroviren, alle HTL-Viren, humanes T-cell leu
kämie-Virus, Oncornaviren, Spumaviren, Lentiviren, Alle HI-
Viren,
Filoviridae: Marburg- und Ebolavirus,
Slow-virus-Infektionen, Prionen,
Onkoviren, Leukämie-Viren.The active compounds according to the invention can also be used in particular for infections with the following viruses:
Parvoviridae: Parvoviruses, Dependoviruses, Densoviruses,
Adenoviridae: adenoviruses, mastadenoviruses, aviadenoviruses,
Papovaviridae: papovaviruses, in particular papillomaviruses (so-called wart viruses), polyomaviruses, in particular JC virus, BK virus, and miopapovaviruses,
Herpesviridae: all herpes viruses, in particular herpes simplex viruses, the varicella / zoster viruses, human cytomegalovirus, Epstein-Barr viruses, all human herpes viruses, human herpes virus 6, human herpes virus 7, human herpes virus 8,
Poxviridae: smallpox viruses, Orthopox, Parapox, Molluscum Contagiosum virus, Aviviruses, Capriviruses, Leporipoxviruses,
all primarily hepatotropic viruses, hepatitis viruses: hepatitis A viruses, hepatitis B viruses, hepatitis C viruses, hepatitis D viruses, hepatitis E viruses, hepatitis F viruses, hepatits G viruses,
Hepadnaviruses: all hepatitis viruses, hepatitis B virus, He patitis D viruses,
Picornaviridae: Picornaviruses, all enteroviruses, all polioviruses, all Coxsackieviruses, all echoviruses, all rhinoviruses, He patitis A virus, aphthoviruses,
Calciviridae: hepatitis E viruses,
Reoviridae: reoviruses, orbiviruses, rotaviruses,
Togaviridae: Togaviren, Alphaviren ,, Rubiviren, Pestiviren, Rubellavirus,
Flaviviridae: flaviviruses, TBE virus, hepatitis C virus,
Orthomyxoviridae: all influenza viruses,
Paramyxoviridae: paramyxoviruses, morbillivirus, pneumovirus, measles virus, mumps virus,
Rhabdoviridae: rhabdoviruses, rabies virus, lyssavirus, viscous stomatitis virus,
Coronaviridae: Coronaviruses,
Bunyaviridae: Bunyaviren, Nairovirus, Phlebovirus, Uukuvirus, Hantavirus,
Arenaviridae: arenaviruses, lymphocytic choriomeningitis virus,
Retroviridae: retroviruses, all HTL viruses, human T-cell leu kemia virus, oncornaviruses, spumaviruses, lentiviruses, all HI viruses,
Filoviridae: Marburg and Ebola viruses, slow virus infections, prions, onkoviruses, leukemia viruses.
Die erfindungsgemäßen Bisphosphonate sind somit zur Bekämpfung
folgender viraler Infekte geeignet:
Eradikation von Papillomaviren zur Vorbeugung von Tumoren,
insbesondere von Tumoren der Geschlechtsorganen verursacht
durch Papillomaviren beim Menschen, Eradikation von JC-Viren
und BK-Viren, Eradikation von Herpesviren, Eradikation humaner
Herpesviren 8 zur Behandlung der Kaposi-Sarkoma, Eradikation
von Zytomegalie-Viren vor Transplantationen, Eradikation von
Eppstein-Barr-Viren vor Transplantation und zur Vorbeugung von
Eppstein-Barr-Viren-assozierten Tumoren, Eradikation von Hepa
titisviren zur Behandlung von chronischen Leber-Erkrankungen
und zur Vorbeugung von Lebertumoren und Leberzirrhosen, Eradi
kation von Coxsackieviren bei Kardiomyopathien, Eradikation
von Coxsackieviren bei Diabetes-mellitus-Patienten, Eradikati
on von Immunschwäche-Viren in Mensch und Tier, Behandlung von
Begleitinfektionen in AIDS-Patienten, Behandlung von Entzün
dungen viraler Genese des Respirationstraktes (Larynxpapillo
me, Hyberplasien, Rhinitis, Pharyngitis, Bronchitis, Pneumoni
en), der Sinnesorgane (Keratokonjunktivitis), des Nervensy
stems (Poliomyelitis, Meningoenzephalitis, Enzephalitis, suba
kute sklerosierende Panenzephalitis, SSPE, progressive multi
fokale Leukoenzephalopathie, Lymphozytäre Choriomeningitis),
des Magen-Darm-Traktes (Stomatitis, Gingivostomatitis, Ösopha
gitis, Gastritis, Gastroenteritis, Durchfallerkrankungen), der
Leber und des Gallensystems (Hepatitis, Cholangitis, hepato
zelluläres Karzinom), des lymphatischen Gewebes (Mononukleose,
Lymphadenitis), des hämatopoetischen Systems, der Geschlechts
organe (Mumpsorchitis), der Haut (Warzen, Dermatitis, Herpes
labialis, Fieberbläschen, Herpes Zoster, Gürtelrose), der
Schleimhäute (Papillome, Konjunktivapapillome, Hyperplasien,
Dysplasien), des Herz-Blutgefäß-Systems (Arteriitis, Myokardi
tis, Endokarditis, Perikarditis), des Nieren-Harnweg-Systems,
der Geschlechtsorgane (Anogenitale Läsionen, Warzen, Genital
warzen, spitzen Kondylome, Dysplasien, Papillome, Zervix
dysplasien, Condylomata acuminata, Epidermodysplasia verruci
formis), der Bewegungsorgane (Myositis, Myalgien), Behandlung
der Maul- und Klauenseuche der Paarhufer, des Colorado-
Zeckenfiebers, des Dengue-Syndroms, des hämorrhagisches Fie
bers, der Frühsommermeningoenzephalitis (FSME) und des Gelb
fiebers.The bisphosphonates according to the invention are therefore suitable for combating the following viral infections:
Eradication of papillomaviruses for the prevention of tumors, especially tumors of the genital organs caused by papillomaviruses in humans, eradication of JC viruses and BK viruses, eradication of herpes viruses, eradication of human herpes viruses 8 for the treatment of Kaposi's sarcoma, eradication of cytomegaloviruses Transplants, eradication of Eppstein-Barr viruses before transplantation and for the prevention of Eppstein-Barr virus-associated tumors, eradication of Hepa titis viruses for the treatment of chronic liver diseases and for the prevention of liver tumors and cirrhosis, eradication of Coxsackieviruses in cardiomyopathies, Eradication of Coxsackieviruses in diabetes mellitus patients, eradication of immunodeficiency viruses in humans and animals, treatment of concomitant infections in AIDS patients, treatment of inflammation of the viral genesis of the respiratory tract (laryngeal papillo me, hyberplasia, rhinitis, pharyngitis, bronchitis, pneumoni en), the sensory organ ne (keratoconjunctivitis), of the Nervensy stems (poliomyelitis, meningoencephalitis, encephalitis, suba kute sclerosing panencephalitis, SSPE, progressive multi-focal leukoencephalopathy, lymphocytic choriomeningitis), of the gastrointestinal tract (stomatitis, gingivostomatitis, Ösopha Gitis gastritis, gastroenteritis, diarrhea ), the liver and the biliary system (hepatitis, cholangitis, hepato cellular carcinoma), the lymphatic tissue (mononucleosis, lymphadenitis), the hematopoietic system, the genital organs (mumpsorchitis), the skin (warts, dermatitis, herpes labialis, cold sores, herpes Zoster, shingles), the mucous membranes (papillomas, conjunctival apillomas, hyperplasias, dysplasias), the cardiovascular system (arteritis, myocarditis, endocarditis, pericarditis), the kidney-urinary system, the genital organs (anogenital lesions, warts, genitalia warts, pointed condylomas, dysplasias, papillomas, cervical dysplasias, condylomata acuminata, Epidermodysplasia verruci formis), the locomotive organs (myositis, myalgia), treatment of foot and mouth disease of the cloven hoofed animals, Colorado tick fever, dengue syndrome, hemorrhagic fever, early summer meningoencephalitis (TBE) and yellow fever.
Die Aktivität der Substanzen wird in einem Versuchssystem be stimmt. Dieses System beruht auf die Messung der Inhibition des Wachstums von Bakterien, Parasiten, Viren, Pilze oder Pflanzen in vitro. Hierzu werden zum Teil Versuchsverfahren verwendet, die dem Fachmann bekannt sind.The activity of the substances is in a test system Right. This system is based on the measurement of inhibition the growth of bacteria, parasites, viruses, fungi or Plants in vitro. To this end, test procedures are used in part used, which are known to the expert.
Zum Beispiel wird zur Bestimmung der Antimalaria Aktivität die Inhibition des Wachstums von Malaria Parasiten in Blutkulturen bestimmt. For example, to determine antimalaria activity Inhibition of the growth of malaria parasites in blood cultures certainly.
Die Bestimmung der antibakteriellen Aktivität beruht auf Mes sung der Hemmung von Bakterienwachstum auf Nährböden und in Flüssigkulturen.The determination of the antibacterial activity is based on Mes inhibition of bacterial growth on nutrient media and in Liquid cultures.
Die Bestimmung der antiviralen Aktivität beruht auf Inhibition der Bildung von viralen Elementen in Zellkulturen.The determination of the antiviral activity is based on inhibition the formation of viral elements in cell cultures.
Die Bestimmung der fungiziden Aktivität beruht auf Inhibition des Wachstums von Pilzen auf Nährböden und in Flüssigkulturen. Einige der Mikroorganismen, die untersucht werden sollen, kön nen nur in Tiermodellen untersucht werden. Hier werden die entsprechenden Modelle angewendet.The determination of the fungicidal activity is based on inhibition the growth of fungi on nutrient media and in liquid cultures. Some of the microorganisms to be examined can can only be examined in animal models. Here are the corresponding models applied.
Substanzen, die eine Wirksamkeit in den in vitro Meßsystemen zeigen, werden in in vivo Modellen weiter untersucht. Die an tiparasitäre, antivirale, fungizide oder antibakterielle Akti vität wird in den entsprechenden Tiermodelle weiter evaluiert.Substances that are effective in in vitro measurement systems show are further investigated in in vivo models. The on tiparasitary, antiviral, fungicidal or antibacterial acti vity is further evaluated in the corresponding animal models.
Das Screefling nach herbizider Aktivität wird mittels Algensy stemen und Messung der Isoprenemission von Pflanzen unter Standardbedingungen bestimmt.Screening for herbicidal activity is carried out using Algensy systems and measurement of isoprene emissions from plants under Standard conditions determined.
Die Mittel können in Kombination mit anderen Mitteln mit anti viralen Eigenschaften eingesetzt werden.The agents can be combined with other agents with anti viral properties are used.
Als bevorzugte pharmazeutische Zubereitungen seien Tabletten, Dragees, Kapseln, Pillen, Granulate, Suppositorien, Lösungen, Suspensionen und Emulsionen, Pasten, Salben, Gele, Cremes, Lo tions, Puder und Sprays genannt. Tabletten, Dragees, Kapseln, Pillen und Granulate können den oder die Wirkstoffe neben den üblichen Trägerstoffen enthalten, wie (a) Füll- und Streckmit tel, z. B. Stärken, Milchzucker, Rohrzucker, Glukose, Mannit und Kieselsäure, (b) Bindemittel, z. B. Carboxymethylcellulo se, Alginate, Gelatine, Polyvinylpyrrolidon, (c) Feuchthal temittel, z. B. Glycerin, (d) Sprengmittel, z. B. Agar-Agar, Calciumcarbonat und Natriumcarbonat, (e) Lösungsverzögerer, z. B. Paraffin und (f) Resorptionsbeschleuniger, z. B. quarternä re Ammoniumverbindungen, (g) Netzmittel, z. B. Cetylalkohol, Glycerinmonostearat, (h) Adsorptionsmittel, z. B. Kaolin und Bentonit und (i) Gleitmittel, z. B. Talkum, Calcium- und Ma gnesiumstearat und feste Polyethylenglykole oder Gemische der unter (a) bis (i) aufgeführten Stoffe.The preferred pharmaceutical preparations are tablets, Coated tablets, capsules, pills, granules, suppositories, solutions, Suspensions and emulsions, pastes, ointments, gels, creams, lo tion, powder and sprays called. Tablets, coated tablets, capsules, Pills and granules can be the active ingredient or ingredients in addition to the contain conventional carriers, such as (a) filling and stretching tel, e.g. B. starches, milk sugar, cane sugar, glucose, mannitol and silica, (b) binders, e.g. B. Carboxymethyl cellulo se, alginates, gelatin, polyvinylpyrrolidone, (c) damp means, e.g. B. glycerin, (d) disintegrant, e.g. B. agar, Calcium carbonate and sodium carbonate, (e) solution retarders, e.g. B. paraffin and (f) absorption accelerator, e.g. B. quaternary re ammonium compounds, (g) wetting agents, e.g. B. cetyl alcohol, Glycerol monostearate, (h) adsorbent, e.g. B. kaolin and Bentonite and (i) lubricants, e.g. B. talc, calcium and Ma magnesium stearate and solid polyethylene glycols or mixtures of substances listed under (a) to (i).
Die Tabletten, Dragees, Kapseln, Pillen und Granulate können mit den üblichen, gegebenenfalls Opakisierungsmittel enthal tenden Überzügen und Hüllen versehen sein und auch so zusam mengesetzt sein, daß sie den oder die Wirkstoffe nur oder be vorzugt in einem bestimmten Teil des Intestinaltraktes gegebe nenfalls verzögert abgeben, wobei als Einbettungsmassen z. B. Polymersubstanzen und Wachse verwendet werden können.The tablets, dragees, capsules, pills and granules can with the usual, optionally containing opacifiers tendency coatings and covers and so together be set that they only or be the active ingredients preferably in a certain part of the intestinal tract If necessary, deliver with a delay, with z. B. Polymer substances and waxes can be used.
Der oder die Wirkstoffe können gegebenenfalls mit einem oder mehreren der oben angegebenen Trägerstoffe auch in mikrover kapselter Form vorliegen.The active ingredient (s) can optionally be combined with an or several of the above-mentioned carriers also in microver encapsulated form.
Suppositorien können neben dem oder den Wirkstoffen die übli chen wasserlöslichen oder wasserunlöslichen Trägerstoffe ent halten, z. B. Polyethylenglykole, Fette, z. B. Kakaofett und höhere Ester (z. B. C14-Alkohol mit C16-Fettsäure) oder Gemi sche dieser Stoffe.Suppositories in addition to the active ingredient (s) can contain the usual water-soluble or water-insoluble carriers, e.g. B. polyethylene glycols, fats, e.g. B. cocoa fat and higher esters (e.g. C 14 alcohol with C 16 fatty acid) or mixtures of these substances.
Salben, Pasten, Cremes und Gele können neben dem oder den Wirkstoffen die üblichen Trägerstoffe enthalten, z. B. tieri sche und pflanzliche Fette, Wachse, Paraffine, Stärke, Tra gant, Cellulosederivate, Polyethylenglykole, Silikone, Bento nite, Kieselsäure, Talkum und Zinkoxid oder Gemische dieser Stoffe.Ointments, pastes, creams and gels can next to the or Active substances contain the usual carriers, e.g. B. tieri vegetable and vegetable fats, waxes, paraffins, starch, tra gant, cellulose derivatives, polyethylene glycols, silicones, bento nite, silica, talc and zinc oxide or mixtures of these Fabrics.
Puder und Sprays können neben dem oder den Wirkstoffen die üb lichen Trägerstoffe enthalten, z. B. Milchzucker, Talkum, Kie selsäure, Aluminiumhydroxid, Calciumsilikat und Polyamidpulver oder Gemische dieser Stoffe. Sprays können zusätzlich die üb lichen Treibmittel, z. B. Chlorfluorkohlenwasserstoffe, ent halten.Powders and sprays can in addition to the active ingredient (s) Lichen carriers included, for. B. milk sugar, talc, Kie silica, aluminum hydroxide, calcium silicate and polyamide powder or mixtures of these substances. Sprays can also be used union blowing agents, e.g. B. chlorofluorocarbons, ent hold.
Lösungen und Emulsionen können neben dem oder den Wirkstoffen die üblichen Trägerstoffe wie Lösungsmittel, Lösungsvermittler und Emulgatoren, z. B. Wasser, Ethylalkohol, Isopropylalkohol, Ethylcarbonat, Ethylacetat, Benzylalkohol, Benzylbenzoat, Pro pylenglykol, 1,3-Butylenglykol, Dimethylformamid, Öle, insbe sondere Baumwollsaatöl, Erdnußöl, Maiskeimöl, Olivenöl, Ricinusöl und Sesamöl, Glycerin, Glycerinformal, Tetrahydro furfurylalkohol, Polyethylenglykole und Fettsäureester des Sorbitans oder Gemische dieser Stoffe enthalten.Solutions and emulsions can be added to the active ingredient (s) the usual carriers such as solvents, solubilizers and emulsifiers, e.g. B. water, ethyl alcohol, isopropyl alcohol, Ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Pro pylene glycol, 1,3-butylene glycol, dimethylformamide, oils, esp special cottonseed oil, peanut oil, corn oil, olive oil, Castor oil and sesame oil, glycerin, glycerin formal, tetrahydro furfuryl alcohol, polyethylene glycols and fatty acid esters of Contain sorbitans or mixtures of these substances.
Zur parenteralen Applikation können die Lösungen und Emulsio nen auch in steriler und blutisotonischer Form vorliegen.The solutions and emulsions can be used for parenteral administration are also available in sterile and blood isotonic form.
Suspensionen können neben dem oder den Wirkstoffen die übli chen Trägerstoffe wie flüssige Verdünnungsmittel, z. B. Was ser, Ethylalkohol, Propylenglykol, Suspendiermittel, z. B. ethoxylierte Isostearylalkohole, Polyoxyethylensorbit- und Sorbitan-Ester, mikrokristalline Cellulose, Aluminiummetahy droxid, Bentonit, Agar-Agar und Tragant oder Gemische dieser Stoffe enthalten.Suspensions can besides the active ingredient (s) the usual Chen carriers such as liquid diluents, e.g. B. What water, ethyl alcohol, propylene glycol, suspending agents, e.g. B. ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and Sorbitan esters, microcrystalline cellulose, aluminum metal hydroxide, bentonite, agar and tragacanth or mixtures of these Contain substances.
Die genannten Formulierungsformen können auch Färbemittel, Konservierungsstoffe sowie geruchs- und geschmacksverbesserte Zusätze, z. B. Pfefferminzöl und Eukalyptusöl und Süßmittel, z. B. Saccharin, enthalten.The formulation forms mentioned can also contain colorants, Preservatives as well as smell and taste-improved Additives, e.g. B. peppermint oil and eucalyptus oil and sweeteners, e.g. B. saccharin.
Bisphosphonsäuren und ihre Derivate der Formel (I) sollen in den oben aufgeführten pharmazeutischen Zubereitungen, vorzugs weise in einer Konzentration von etwa 0,1 bis 99,5 Gew.-%, vorzugsweise von etwa 0,5 bis 95 Gew.-%, der Gesamtmischung vorhanden sein.Bisphosphonic acids and their derivatives of the formula (I) are said to the pharmaceutical preparations listed above, preferred wise in a concentration of about 0.1 to 99.5% by weight, preferably from about 0.5 to 95% by weight of the total mixture to be available.
Die oben aufgeführten pharmazeutischen Zubereitungen können außer den Verbindungen der Formel (I) auch weitere pharmazeu tische Wirkstoffe enthalten.The pharmaceutical preparations listed above can in addition to the compounds of formula (I) also other pharmazeu contain active ingredients.
Die Herstellung der oben aufgeführten pharmazeutischen Zube reitungen erfolgt in üblicher Weise nach bekannten Methoden, z. B. durch Mischen des oder der Wirkstoffe mit dem oder den Trägerstoffen.The manufacture of the pharmaceutical accessories listed above Horse riding is done in the usual way according to known methods, e.g. B. by mixing the active ingredient or ingredients with the or Carriers.
Die genannten Zubereitungen können bei Mensch und Tier entwe der oral, rektal, parenteral (intravenös, intramuskulär, sub kutan), intracisternal, intravaginal, intraperitoneal, lokal (Puder, Salbe, Tropfen) und zur Therapie von Infektionen in Hohlräumen, Körperhöhlen angewendet werden. Als geeignete Zu bereitungen kommen Injektionslösungen, Lösungen und Suspensio nen für die orale Therapie, Gele, Aufgußformulierungen, Emul sionen, Salben oder Tropfen in Frage. Zur lokalen Therapie können ophtalmologische und dermatologische Formulierungen, Silber- und andere Salze, Ohrentropfen, Augensalben, Puder oder Lösungen verwendet werden. Bei Tieren kann die Aufnahme auch über das Futter oder Trinkwasser in geeigneten Formulie rungen erfolgen. Ferner können Gele, Pulver, Puder, Tabletten, Retard-Tabletten, Premixe, Konzentrate, Granulate, Pellets, Tabletten, Boli, Kapseln, Aerosole, Sprays, Inhalate bei Mensch und Tier angewendet werden. Ferner können die erfin dungsgemäßen Verbindungen in andere Trägermaterialien wie zum Beispiel Kunststoffe, (Kunststoffketten zur lokalen Therapie), Kollagen oder Knochenzement eingearbeitet werden.The preparations mentioned can be used in humans and animals the oral, rectal, parenteral (intravenous, intramuscular, sub cutaneous), intracisternal, intravaginal, intraperitoneal, local (Powder, ointment, drops) and for the treatment of infections in Cavities, body cavities are applied. As a suitable addition Preparations come with injection solutions, solutions and suspensions NEN for oral therapy, gels, infusion formulations, emul ions, ointments or drops. For local therapy ophthalmic and dermatological formulations, Silver and other salts, ear drops, eye ointments, powder or solutions are used. In animals, the intake also in suitable form via the feed or drinking water take place. Gels, powders, powders, tablets, Prolonged-release tablets, premixes, concentrates, granules, pellets, Tablets, boluses, capsules, aerosols, sprays, inhalants Humans and animals can be used. Furthermore, the inventions compounds according to the invention in other carrier materials such as Example plastics, (plastic chains for local therapy), Collagen or bone cement can be incorporated.
Die notwendige Menge der einzelnen Derivate zur Erzielung des gewünschten Effektes unterscheiden sich sehr stark. Im allge meinen hat es sich sowohl in der Human- als auch in der Vete rinärmedizin als vorteilhaft erwiesen, den oder die Bisphos phonate der Formel (I) in Gesamtmengen von etwa 0,005 bis etwa 200 mg/kg Körpergewicht je 24 Stunden, gegebenenfalls in Form mehrerer Einzelgaben, zur Erzielung der gewünschten Ergebnisse zu verabreichen. Eine Einzelgabe enthält den oder die Wirk stoffe vorzugsweise in Mengen von etwa 0,002 bis etwa 50 mg/kg Körpergewicht. Es kann jedoch erforderlich sein, von den ge nannten Dosierungen abzuweichen, und zwar in Abhängigkeit von der Art und dem Körpergewicht des zu behandelnden Patienten, der Art und der Schwere der Erkrankung, der Art der Zuberei tung und der Applikation des Arzneimittels sowie dem Zeitraum bzw. Intervall, innerhalb welchem die Verabreichung erfolgt.The necessary amount of the individual derivatives to achieve the desired effect differ very much. Generally it was mine both in the human and in the vete binary medicine has proven to be beneficial to the bisphos Phonates of formula (I) in total from about 0.005 to about 200 mg / kg body weight per 24 hours, optionally in form several single doses to achieve the desired results to administer. A single dose contains the effect fabrics preferably in amounts from about 0.002 to about 50 mg / kg Body weight. However, it may be necessary from the ge named doses vary, depending on the type and body weight of the patient to be treated, the type and severity of the disease, the type of preparation and the application of the drug and the period or interval within which the administration takes place.
So kann es in einigen Fällen ausreichend sein, mit weniger als der obengenannten Menge Wirkstoff auszukommen, während in an deren Fällen die oben angeführte Wirkstoffmenge überschritten werden muß. Die Festlegung der jeweils erforderlichen optima len Dosierung und Applikationsart der Wirkstoffe kann durch den Fachmann aufgrund seines Fachwissens erfolgen.So in some cases it may be sufficient with less than the above amount of active ingredient to get by while in at whose cases exceeded the amount of active ingredient mentioned above must become. The determination of the optima required in each case len dosage and type of application of the active ingredients can by the specialist on the basis of his specialist knowledge.
Bei der Behandlung von Tieren können die erfindungsgemäß zu verwendenden Verbindungen in den üblichen Konzentrationen und Zubereitungen zusammen mit dem Futter bzw. mit Futterzuberei tungen oder mit dem Trinkwasser gegeben werden.In the treatment of animals, the can according to the invention using compounds in the usual concentrations and Preparations together with the feed or with feed preparation or with drinking water.
Claims (8)
worin
A1, A2, A3, A4, die gleich oder verschieden sein können, aus der Gruppe ausgewählt sind, die aus Wasserstoff, substitu iertem und unsubstituiertem Alkyl, substituiertem und un substituiertem Aryl, substituiertem und unsubstituiertem Aralkyl, substituiertem und unsubstituiertem Cycloalkyl, substituiertem und unsubstituiertem heterocyclischen Rest, Metallen der 1., 2. und 3. Hauptgruppe des periodischen Sy stems, wie Na, K, Ca, Mg, Al sowie substituiertem und un substituiertem Ammonium und Ammoniumverbindungen, die sich von Ethylendiamin oder Aminosäuren ableiten, besteht,
X, das auch wegfallen kann, aus der Gruppe ausgewählt ist, die aus Alkylen, Alkenylen und Hydroxyalkylen besteht,
R1, R2, die gleich oder verschieden sein können, aus der Gruppe ausgewählt sind, die aus H, OH, -NH2, substituiertem und unsubstituiertem Acyl, substituiertem und unsubstitu iertem Alkyl, substituiertem und unsubstituiertem Aryl, substituiertem und unsubstituiertem Cycloalkyl, substitu iertem und unsubstituiertem Aralkyl, substituiertem und un substituiertem heterocyclischen Rest und -SR3, Cl und -NR3R4 besteht, worin
R3, R4, die gleich oder verschieden sein können, aus der Gruppe ausgewählt sind, die aus H, OH, substituiertem und unsubstituiertem Acyl, substituiertem und unsubstituiertem Alkyl, substituiertem und unsubstituiertem Aryl, substitu iertem und unsubstituiertem Aralkyl, substituiertem und un substituiertem Cycloalkyl und substituiertem und unsubsti tuiertem heterocyclischen Rest besteht, und
deren pharmazeutisch verträglichen Salzen, Amiden, Estern sowie Salzen der Ester oder Verbindungen, die bei Applika tion die zu verabreichenden Verbindungen als Stoffwechsel- oder Abbauprodukte bilden, zur therapeutischen und prophy laktischen Behandlung von infektiösen Prozessen bei Mensch und Tier, die durch Viren, Bakterien, Pilze oder Parasiten hervorgerufen werden und als Fungizid, Bakterizid oder Her bizid bei Pflanzen.1. Use of bisphosphonic acids of the general formula
wherein
A 1 , A 2 , A 3 , A 4 , which may be the same or different, are selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted cycloalkyl , substituted and unsubstituted heterocyclic radical, metals of the 1st, 2nd and 3rd main group of the periodic system, such as Na, K, Ca, Mg, Al and substituted and unsubstituted ammonium and ammonium compounds derived from ethylenediamine or amino acids, consists,
X, which can also be omitted, is selected from the group consisting of alkylene, alkenylene and hydroxyalkylene,
R 1 , R 2 , which may be the same or different, are selected from the group consisting of H, OH, -NH 2 , substituted and unsubstituted acyl, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic radical and -SR 3 , Cl and -NR 3 R 4 , wherein
R 3 , R 4 , which may be the same or different, are selected from the group consisting of H, OH, substituted and unsubstituted acyl, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted Cycloalkyl and substituted and unsubstituted heterocyclic radical, and
their pharmaceutically acceptable salts, amides, esters and salts of the esters or compounds which, when applied, form the compounds to be administered as metabolic or degradation products for the therapeutic and prophy-lactic treatment of infectious processes in humans and animals caused by viruses, bacteria, Fungi or parasites are caused and as a fungicide, bactericide or herbicide in plants.
worin
A1, A2, A3, A4, die gleich oder verschieden sein können, aus der Gruppe ausgewählt sind, die aus Wasserstoff, substitu iertem und unsubstituiertem Alkyl, substituiertem und un substituiertem Aryl, substituiertem und unsubstituiertem Aralkyl, substituiertem und unsubstituiertem Cycloalkyl, substituiertem und unsubstituiertem heterocyclischen Rest, den Metallen der 1., 2. oder 3. Hauptgruppe des periodi schen Systems, wie Na, K, substituiertem und unsubstituier tem Ammonium und Ammoniumverbindungen, die sich von Ethy lendiamin oder Aminosäuren ableiten, besteht,
X, das auch wegfallen kann, aus der Gruppe ausgewählt ist, die aus Alkyl, (CH2)0-6, insbesondere (CH2)1-5 und Amidino be steht,
R1 aus der Gruppe ausgewählt ist, die aus H, OH, NH2, -CH3 besteht, und
R2 aus der Gruppe ausgewählt ist, die aus
besteht,
zur therapeutischen und prophylaktischen Behandlung von in fektiösen Prozessen bei Mensch und Tier, die durch Viren, Bakterien, Pilze oder Parasiten hervorgerufen werden und als Fungizid, Bakterizid oder Herbizid bei Pflanzen.2. Use of bisphosphonic acids of the formula (I),
wherein
A 1 , A 2 , A 3 , A 4 , which may be the same or different, are selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted cycloalkyl , substituted and unsubstituted heterocyclic radical, the metals of the 1st, 2nd or 3rd main group of the periodic system, such as Na, K, substituted and unsubstituted ammonium and ammonium compounds derived from ethylenediamine or amino acids,
X, which can also be omitted, is selected from the group consisting of alkyl, (CH 2 ) 0-6 , in particular (CH 2 ) 1-5 and amidino,
R 1 is selected from the group consisting of H, OH, NH 2 , -CH 3 , and
R 2 is selected from the group consisting of
consists,
for the therapeutic and prophylactic treatment of in fectious processes in humans and animals, which are caused by viruses, bacteria, fungi or parasites and as a fungicide, bactericide or herbicide in plants.
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19859668A DE19859668A1 (en) | 1998-06-24 | 1998-12-23 | Treating or preventing viral, bacterial, fungal or parasitic infections using bis-phosphonic acid compounds, also having herbicidal activity |
AU30433/00A AU754862B2 (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for the prevention and treatment of infectious processes |
DE59907659T DE59907659D1 (en) | 1998-12-23 | 1999-12-23 | USE OF BISPHOSPHONATES FOR PROPHYLAXIS AND TREATMENT OF INFECTIOUS PROCESSES |
IL14346999A IL143469A0 (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for the prevention and treatment of infectious processes |
PL99349438A PL349438A1 (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for the prevention and treatment of infectious processes |
CA002356262A CA2356262A1 (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for the prevention and treatment of infectious processes |
JP2000590614A JP2002533385A (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for prevention and treatment of infectious diseases |
PCT/EP1999/010350 WO2000038660A2 (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for the prevention and treatment of infectious processes |
DK99964669T DK1140113T3 (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for prophylaxis and treatment of infectious processes |
EP99964669A EP1140113B1 (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for the prevention and treatment of infectious processes |
TR2001/01841T TR200101841T2 (en) | 1998-12-23 | 1999-12-23 | The use of bisphosphonates to prevent infections and treat infections |
ES99964669T ES2205930T3 (en) | 1998-12-23 | 1999-12-23 | USE OF BISPHOSPHONATE ACIDS. |
US09/868,961 US6696427B1 (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for the prevention and treatment of infectious processes |
MXPA01006473A MXPA01006473A (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for the prevention and treatment of infectious processes. |
CZ20012231A CZ20012231A3 (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for prophylaxis and for treating infection processes |
BR9916850-2A BR9916850A (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for the prophylaxis and treatment of infectious processes |
CN99814903A CN1331597A (en) | 1998-12-23 | 1999-12-23 | Use of bisphosphonates for prevention and treatment of infectious processes |
PT99964669T PT1140113E (en) | 1998-12-23 | 1999-12-23 | USE OF BISPHOSPHANTS FOR PROPHYLAXIS AND TREATMENT OF INFECTIOUS PROCESSES |
AT99964669T ATE253368T1 (en) | 1998-12-23 | 1999-12-23 | USE OF BISPHOSPHONATES FOR PROPHYLAXIS AND TREATMENT OF INFECTIOUS PROCESSES |
IS5956A IS5956A (en) | 1998-12-23 | 2001-05-30 | Use of bisphosphonic acid for the prevention and treatment of infection processes |
NO20013167A NO20013167D0 (en) | 1998-12-23 | 2001-06-22 | Use of bisphosphonates for the prevention and treatment of infection processes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19827986 | 1998-06-24 | ||
DE19859668A DE19859668A1 (en) | 1998-06-24 | 1998-12-23 | Treating or preventing viral, bacterial, fungal or parasitic infections using bis-phosphonic acid compounds, also having herbicidal activity |
Publications (1)
Publication Number | Publication Date |
---|---|
DE19859668A1 true DE19859668A1 (en) | 1999-12-30 |
Family
ID=7871770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19859668A Ceased DE19859668A1 (en) | 1998-06-24 | 1998-12-23 | Treating or preventing viral, bacterial, fungal or parasitic infections using bis-phosphonic acid compounds, also having herbicidal activity |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE19859668A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000030653A2 (en) * | 1998-11-25 | 2000-06-02 | Jomaa Pharmaka Gmbh | Use of phosphonoformic acid derivatives for treating infections |
US7358361B2 (en) | 2004-10-08 | 2008-04-15 | The Board Of Trustees Of The University Of Illinois | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US7687482B2 (en) | 2006-03-17 | 2010-03-30 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
WO2011023624A1 (en) * | 2009-08-26 | 2011-03-03 | Humboldt-Universität Zu Berlin | Bisphosphonates as inhibitors of acid sphingomyelinase |
US8012949B2 (en) | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
-
1998
- 1998-12-23 DE DE19859668A patent/DE19859668A1/en not_active Ceased
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000030653A2 (en) * | 1998-11-25 | 2000-06-02 | Jomaa Pharmaka Gmbh | Use of phosphonoformic acid derivatives for treating infections |
WO2000030653A3 (en) * | 1998-11-25 | 2000-11-16 | Hassan Jomaa | Use of phosphonoformic acid derivatives for treating infections |
US7358361B2 (en) | 2004-10-08 | 2008-04-15 | The Board Of Trustees Of The University Of Illinois | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US7745422B2 (en) | 2004-10-08 | 2010-06-29 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US8012949B2 (en) | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
US8071573B2 (en) | 2004-10-08 | 2011-12-06 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US7687482B2 (en) | 2006-03-17 | 2010-03-30 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
WO2011023624A1 (en) * | 2009-08-26 | 2011-03-03 | Humboldt-Universität Zu Berlin | Bisphosphonates as inhibitors of acid sphingomyelinase |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999052515A2 (en) | Use of organophosphoric compounds for the therapeutic and preventative treatment of infections | |
EP1095050A1 (en) | Phosphorous organic compounds and their use | |
EP1140113B1 (en) | Use of bisphosphonates for the prevention and treatment of infectious processes | |
DE19903398A1 (en) | Use of thiadiazole derivatives for the prophylactic and therapeutic treatment of infections | |
DE19920247A1 (en) | Drugs containing compounds containing a nitrogen-oxygen heterocycle as an active ingredient and their use | |
EP1140952B1 (en) | Organo-phosphorus compounds and their utilization | |
EP1133500B1 (en) | Organophosphorous compounds and the use thereof | |
DE19843222A1 (en) | Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections | |
DE19843383A1 (en) | New amino and imino substituted organo-phosphorus compounds useful in medicine against viral, bacterial, fungal and parasiticidal infections and as herbicides, plant fungicides and plant bactericides | |
DE19902924A1 (en) | Use of organophosphorus compounds for the prophylactic and therapeutic treatment of infections | |
DE19859668A1 (en) | Treating or preventing viral, bacterial, fungal or parasitic infections using bis-phosphonic acid compounds, also having herbicidal activity | |
WO2000017212A1 (en) | Organophosphorous compounds and use thereof | |
WO2001060829A1 (en) | Phosphororganic compounds and the use thereof | |
DE10014127A1 (en) | Antibacterial, fungicidal, antiviral, antiparasitic and herbicidal agents for medicinal, veterinary or agricultural use, comprising amino- or imino-substituted organophosphorus compounds having nitrogen-containing spacer group | |
WO2001093872A1 (en) | Use of organophosphorous hydroxamic acid derivatives for producing medicaments | |
DE19843334A1 (en) | New organosulfinic acid and organosulfonic acid derivatives useful in medicine against viral, bacterial, fungal and parasiticidal infections and as herbicides, plant fungicides and plant bactericides | |
DE19831639C1 (en) | Identifying antiparasitic agents used to treat or prevent parasitic infections, especially malaria, sleeping sickness and leishmaniosis | |
DE19843360A1 (en) | New phosphororganic compounds; useful for treatment of bacterial, viral and parasitic infection, and as herbicides or for treating infections in plants | |
DE19903666A1 (en) | Medicines containing 3-isoxazolidinones and hydroxylamic acids as an active ingredient and their use | |
WO2000003699A2 (en) | Drugs containing phosphoric acid derivatives as active ingredient and their use | |
WO1999066875A2 (en) | Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway, and inhibitors of lipid metabolism | |
AU2003261554A1 (en) | Organophosphorus containing preparations and applications therefor | |
CZ2001989A3 (en) | Use of organophosphorous compounds for producing medicaments for the therapeutic and prophylactic treatment of infections or as a fungicide, bactericide or herbicide in plants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8110 | Request for examination paragraph 44 | ||
8127 | New person/name/address of the applicant |
Owner name: JOMAA PHARMAKA GMBH, 35392 GIESSEN, DE |
|
8181 | Inventor (new situation) |
Free format text: JOMAA, HASSAN, DR., 35398 GIESSEN, DE |
|
8127 | New person/name/address of the applicant |
Owner name: BIOAGENCY AG, 22177 HAMBURG, DE |
|
8131 | Rejection |